REGN - Regeneron Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
12,172,900
12,172,900
16,071,700
8,497,100
7,863,400
Cost of revenue
1,560,400
1,560,400
2,437,500
1,119,900
782,200
Gross profit
10,612,500
10,612,500
13,634,200
7,377,200
7,081,200
Operating expenses
Research development
3,592,500
3,592,500
2,908,100
2,735,000
3,036,600
Selling general and administrative
2,115,900
2,115,900
1,824,900
1,346,000
1,834,800
Total operating expenses
5,618,500
5,618,500
4,687,400
3,800,600
4,871,400
Operating income or loss
4,994,000
4,994,000
8,946,800
3,576,600
2,209,800
Interest expense
59,400
59,400
57,300
56,900
30,200
Total other income/expenses net
-235,900
-75,800
436,300
290,700
219,300
Income before tax
4,858,800
4,858,800
9,325,800
3,810,400
2,429,100
Income tax expense
520,400
520,400
1,250,500
297,200
313,300
Income from continuing operations
4,338,400
4,338,400
8,075,300
3,513,200
2,115,800
Net income
4,338,400
4,338,400
8,075,300
3,513,200
2,115,800
Net income available to common shareholders
4,338,400
4,338,400
8,075,300
3,513,200
2,115,800
Basic EPS
-
40.51
76.40
32.65
19.38
Diluted EPS
-
38.22
71.97
30.52
18.46
Basic average shares
-
107,100
105,700
107,600
109,200
Diluted average shares
-
113,500
112,200
115,100
114,600
EBITDA
-
4,918,200
9,383,100
3,867,300
2,209,800